touchLearning Activities
Education, Conference Coverage and Articles
RGB-19 Matches Tocilizumab in Efficacy and Safety: Promising Phase III Data from RA Biosimilar Trial
In this EULAR 2025 interview, Professor Ernest Choy (Cardiff University School of Medicine, UK) discusses the Phase III trial results of RGB-19, a proposed biosimilar to tocilizumab, in adults with active rheumatoid arthritis. He outlines the study’s design, key efficacy and safety findings, and the potential impact of biosimilars like RGB-19 on improving access to biologic therapies.
touchIMMUNOLOGY coverage of EULAR 2025: The 2025 European Alliance of Associations for Rheumatology (EULAR) Congress brought together leading rheumatologists, immunologists, and allied healthcare professionals from across Europe and beyond. Running from June 11–14 in Barcelona, the conference showcased the latest advances in immune-mediated ...
At EULAR 2025, Dr Marina Magrey presented week 52 data from the BE MOBILE 1 and 2 trials, highlighting comparable efficacy of bimekizumab in male and female patients with axial spondyloarthritis. Despite baseline sex differences in symptom duration and disease burden, over 50% of patients achieved ASAS40, supporting bimekizumab’s effectiveness across both radiographic and non-radiographic axSpA.
As part of our EULAR 2025 coverage, Dr Dinesh Khanna discusses early findings from the Breakfree-1 trial investigating BMS-986353, a next-generation CD19 CAR T-cell therapy, in severe, treatment-refractory autoimmune diseases. In this exclusive interview, Dr Khanna explores the rationale, mechanism, and encouraging early results in systemic sclerosis, highlighting robust CAR T expansion, immune reset, and meaningful clinical improvements in skin and lung outcomes.
Watch consultant immunologists Dr Dalm and Dr Chandra outline what APDS is, the common features of this disease and option for diagnosis, treatment and management.
The Phase II ARGO trial evaluated the IL-17A and IL-17F inhibitor sonelokimab in psoriatic arthritis, showing promising clinical efficacy and significant improvements in patient-reported outcomes (PROs). In this interview, Prof. Laure Gossec highlights how sonelokimab reduced disease burden and improved quality of life, emphasizing the importance of PROs in assessing treatment effectiveness and guiding future development.
This interview with Dr Brian Jaros, part of our Future Leaders series, highlights his journey into vasculitis, his passion for medical education, and his outlook on the evolving landscape of rheumatology. He shares insights on mentorship, research, and the importance of leading with enthusiasm to inspire the next generation of clinicians.
Interstitial lung disease (ILD) is a common and potentially fatal complication of systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis (RA) and systemic sclerosis (SSc). ILD may be the first sign of disease or develop later, often with variable clinical courses. Early detection is critical, as delayed diagnosis contributes to poor outcomes. In response, the 2023 American College of Rheumatology (ACR) guidelines emphasize routine screening and risk-based strategies to improve identification and management of SARD-associated ILD (SARD-ILD).
In this Future Leaders interview, Dr Salvatore Oliva discusses his path to paediatric gastroenterology, highlighting his focus on chronic inflammatory conditions like IBD and EGIDs. He shares insights on leading European collaborative research, the integration of innovation into clinical care, and the promise of precision medicine. Dr Oliva also offers guidance for early-career doctors drawn to this dynamic and multidisciplinary field.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
As part of our Future Leaders series, we spotlight Dr Sonali Bracken, a physician-scientist at Duke University advancing rheumatologic care through cutting-edge research on B cells in autoimmunity. Recently awarded the 2024 ACR Distinguished Fellow Award, Dr Bracken shares insights into her path, research focus, and the emerging therapies poised to transform patient outcomes.
As part of our coverage of DDW 2025, we speak with Dr Florian Rieder about the STENOVA trial evaluating AGMB-129 in fibrostenosing Crohn’s disease. He discusses the rationale behind targeting the TGF-β pathway, the trial design, and promising interim findings suggesting localized efficacy and improved stricture symptoms without systemic toxicity.
In this interview with Dr. Stuart Silverman, we discuss his WCO-IOF-ESCEO 2025 presentation on the clinical utility of bone turnover markers (BTMs) in osteoporosis care. BTMs such as s-CTX and s-PINP, standardized by the IOF-IFCC, provide insights into bone remodelling, support treatment monitoring, guide therapy adjustments, and help personalize drug holidays, though they complement rather than replace traditional diagnostic tools.
touchREVIEWS in RMD is proud to welcome Dr Vinod Ravindran to our editorial board. With a distinguished background in clinical rheumatology, medical education, and research, Dr Ravindran is widely recognized for his contributions to advancing care and understanding in the field.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Dr. Vinod Ravindran (Centre for Rheumatology, Calicut, Kerala, India) shares his highlights from RheumaPreg 2025, held in Vienna. The conference covered the full spectrum of pregnancy management in autoimmune rheumatic diseases. Here, he reflects on key insights from expert-led sessions on fertility, immunosuppression, lupus care, and postpartum outcomes.
Nominated Future Leader, Dr Tom Appleton, shares insights into his career, osteoarthritis research, and the role of immunology in shaping future OA treatments. In this interview, Dr Appleton discusses the importance of early intervention, the impact of synovial macrophage dysfunction, and emerging therapies that could revolutionize rheumatology. His work bridges clinical care and research to drive innovation in osteoarthritis management and autoimmune disease.
touchIMMUNOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
